ClinConnect ClinConnect Logo
Search / Trial NCT06555406

Healthy Lifestyles in Bipolar Disorder: Bay Area Study

Launched by UNIVERSITY OF CALIFORNIA, BERKELEY · Aug 12, 2024

Trial Information

Current as of July 04, 2025

Recruiting

Keywords

Sleep Insomnia Circadian Rhythms

ClinConnect Summary

The "Healthy Lifestyles in Bipolar Disorder: Bay Area Study" is a clinical trial that aims to explore how following a time-restricted eating plan might help people with bipolar disorder feel better. Time-restricted eating means eating only during a certain time of day, which researchers believe could help improve mood and daily rhythms in the body. The study will look at how well participants stick to this eating plan and how it relates to their mood changes and overall quality of life. Participants will be asked to keep track of their eating, sleeping, and mood for two weeks before starting the eating plan for eight weeks.

To take part in this study, participants need to be adults diagnosed with bipolar disorder and currently receiving stable medication for their condition. They should also have some sleep issues affecting their daily life. Participants will complete daily surveys and provide information about their eating habits, and they will receive support throughout the study. This research could offer valuable insights into ways to improve the lives of those living with bipolar disorder.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Meets diagnostic criteria for bipolar I disorder or bipolar II disorder (but not cyclothymia, bipolar disorder Not otherwise specified or bipolar disorder due to another medical condition) assessed by the Diagnostic Interview for Anxiety, Mood, and Obsessive-compulsive and Related Neuropsychiatric Disorders \[DIAMOND\])
  • current sleep (insomnia, hypersomnolence) or circadian sleep-wake (delayed phase, advanced phase, irregular sleep-wake, non-24-hour sleep-wake-type) concerns indicated by endorsement of at least some sleep or circadian-related impairment across the screening self-reports or interview
  • Living in an English-speaking country (and one that the researchers have expertise in research procedures and diet)
  • Has been speaking English for at least 10 years, speaks English in the home, or certifies that they are able to understand English well for the study and demonstrates this during the screening interview.
  • Receiving medical care for bipolar disorder (referrals will be provided for those who would like to begin care)
  • Mood-stabilizing medication regimens stable for at least one month
  • \< 5 kg weight change in the past 3 months
  • Currently eating ≥ 12 hours per day at least twice per week
  • Able to operate the camera function and respond to web-based surveys by phone (loaner phones will be provided as needed)
  • Not engaged in current shift work or have other responsibilities such as providing care that would chronically disrupt their sleep (i.e., \> 3 h between 22:00 and 05:00 h for at least 1 day/week)
  • Able to complete 7 days of dietary logs adequately (e.g., at least 2 entries per day, covering at least a 5-hour eating window) during the baseline period
  • Able to complete screening and baseline questionnaires adequately (e.g., not failing more than 1 attention check item with instructed responding; responding to standard multiple-choice items in a mean of \< 2 seconds per item). Where individuals respond to more than 14 items in a row with the same response, their answers will be manually reviewed for possible invalidity.
  • Exclusion criteria include the following:
  • Current episode of depression, hypomania or mania, or psychosis (assessed by the DIAMOND), Participants with acute mood disorder episodes will be encouraged to seek treatment and to consider the study when symptoms have remitted.
  • Eating disorder diagnosis (by self-report of treatment or diagnosis at any point during their life, Short Eating Disorder Examination Questionnaire (EDE-QS) scores above clinical concern thresholds for eating disorders, or DIAMOND interview of symptoms during adulthood)
  • Past 3-month alcohol use disorder or substance use disorder (assessed by DIAMOND)
  • Active suicidal ideation coupled with plan, intent or attempt history as assessed by Columbia Suicide Severity Rating Scale
  • Conditions that would interfere with ability to take part in the intervention, including pregnancy, breastfeeding, uncorrected hypo or hyperthyroidism, gastrointestinal conditions impairing nutrient absorption
  • Conditions that would confound immune or other study measures, such as HIV, AIDS, lupus, or multiple sclerosis
  • Medications contraindicated for fasting: clozapine, glucose-lowering medications, diabetes-related injections, medications requiring food early morning or late evening, corticosteroids; Glucagon-like peptide-1 (GLP-1) agonists will not be an exclusion criteria if weight stabilized
  • Cognitive deficits as noted during the initial interview or as indicated by low performance on the Orientation Memory Concentration Test- Short Version (weighted score \< 20)

About University Of California, Berkeley

The University of California, Berkeley, a leading research institution renowned for its commitment to scientific innovation and academic excellence, serves as a prominent sponsor of clinical trials aimed at advancing medical knowledge and improving patient outcomes. With a robust infrastructure for interdisciplinary collaboration, UC Berkeley leverages its distinguished faculty, cutting-edge laboratories, and extensive resources to conduct research that addresses critical health challenges. The university is dedicated to fostering a culture of ethical research practices and ensuring the highest standards of safety and efficacy in its clinical investigations, ultimately contributing to the translation of scientific discoveries into tangible health solutions.

Locations

Berkeley, California, United States

Patients applied

0 patients applied

Trial Officials

Sheri L Johnson, PhD

Principal Investigator

University of California, Berkeley

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported